

**Minutes of the December 12, 2008  
Pharmacy & Therapeutics (P&T) Committee Meeting  
SD Department of Social Services, Medical Services Division**

**Members present**

Verdayne Brandenburg, M.D.; Dana Darger, R.Ph.; James Engelbrecht, M.D.; William Ladwig, R.Ph.; Dennis Hedge, PharmD.; Rick Holm, M.D.; Debra Farver, PharmD.; Timothy Soundy, M.D.

**Members absent**

Willis Sutliff, M.D.  
Galen Goeden, R.Ph.

**DSS staff present**

Mike Jockheck, R.Ph.; Larry Iversen

**HID staff present**

Candace Rieth, Pharm.D.

**Administrative Business**

The P&T meeting was called to order by chair, D. Darger, at approximately 1pm. The minutes of the September 8, 2008 meeting were presented. B. Ladwig made a motion to approve as written, with a second by R. Holm. The motion was approved unanimously.

**Prior Authorization Statistics**

C. Rieth presented an overview of the prior authorization (PA) activity for September 2008. There were a total of 1,887 PAs processed in the month of September, with 99.63% of those requests responded to in less than 8 hours. There were 1,676 (89%) requests received electronically and 211 (11%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

**Analysis of the Top 15 Therapeutic Classes**

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 04/01/2008 – 06/30/2008. The top five classes were antipsychotics, anticonvulsants, cerebral stimulants, proton-pump inhibitors, and antidepressants. The top 15 therapeutic classes make up 42.78% of total claims.

**Duplicate Antipsychotic Therapy**

Committee members asked for information regarding duplicate antipsychotic utilization. C. Rieth presented utilization information for the antipsychotics including patients with multiple antipsychotic scripts. T. Soundy made a motion to recommend that the State investigate duplicate antipsychotic therapy, further. T. Soundy suggested that this be done through an internal peer review process. R. Holm seconded the motion. D. Yocum spoke against prior authorization of antipsychotics. P. Arens, representing NAMI, spoke against prior authorization

of antipsychotics. R. Sang, a local practitioner spoke against prior authorization of antipsychotics. The motion was approved unanimously.

### **Invega Review**

Invega review tabled.

### **Antidepressant Review**

C. Rieth provided the committee with a draft provider letter regarding a two-tiered process for antidepressants. V. Brandenburg made a motion to send the letter to providers. B. Ladwig seconded the motion. A provider letter will be sent prior to the next meeting.

### **Quantity Limits**

C. Rieth presented the committee with a list of quantity limit suggestions. B. Ladwig made a motion to implement the quantity limits listed. D. Farver seconded the motion. S. Schmitz, representing Glaxo, spoke regarding limits on Requip XL. The motion was approved unanimously.

### **Singulair Review**

In response to a previous request from the committee, C. Rieth presented information regarding diagnoses codes submitted on patients utilizing Singulair. V. Brandenburg made a motion to place Singulair on prior authorization with an automatic approval on the first prescription received by a recipient. J. Engelbrecht seconded the motion. M. Stafford, representing Merck, requested that the committee members table the motion until he can provide additional data. V. Brandenburg made a motion to table. R. Holm seconded. The motion was tabled until the committee receives additional data.

### **Altabax Review**

C. Rieth reviewed Altabax utilization with committee members. B. Ladwig made a motion to place a 5g quantity limit on Altabax with a prior authorization for larger tubes. T. Soundy seconded the motion. Motion passed unanimously.

### **Vusion Review**

C. Rieth reviewed Vusion utilization with committee members. R. Holm made a motion to place Vusion on prior authorization. T. Soundy seconded the motion. Motion passed unanimously.

### **Xopenex Review**

C. Rieth reviewed Xopenex utilization with committee members. V. Brandenburg made a motion to send educational letters stating the cost factor of Xopenex. R. Holm seconded the motion. S. Hylla, representing Sepracor, spoke against prior authorization of Xopenex. Motion passed unanimously.

Because of time restraints, it was requested that the meeting be adjourned. Lyrica will be tabled until the March meeting. The next meeting date is March 13, 2009. The location will be sent to members and interested parties as soon as possible. The SD Medicaid P&T meeting was adjourned at 3:00pm.